Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van Hout

Showing results (51-60 of 126) with videos related to

Pageof 13
Sort By:
Prevention Science : the Official Journal of the Society for Prevention Research|March 4, 2011
Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behaviorMaartje A Raaijmakers, Jocelyne A Posthumus, Ben A van Hout, et al.
BMJ (Clinical Research Ed.)|July 26, 1997
Bone density and risk of hip fracture in men and women: cross sectional analysisC E De Laet, B A van Hout, H Burger, et al.
Pharmacoeconomics|September 19, 2002
Costs and effectiveness of using coumarins before, during and after coronary angioplastyJurrien M ten Berg, Johannas C Kelder, Thys H W Plokker, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2003
Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term useR M Klok, M J Postma, B A van Hout, et al.
Journal of Market Access & Health Policy|July 24, 2018
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UKEmilie Clay, Aurélien Jamotte, Peter Verhamme, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 18, 1998
[Economic evaluation of cardiology; background and application]B A van Hout, E S Goes, E W Grijseels, et al.
Clinical Therapeutics|May 17, 2003
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The NetherlandsBen A van Hout, Rogier M Klok, Jacobus R B J Brouwers, et al.
Anti-Cancer Drugs|May 18, 1999
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancerM G Groener, B M van Ineveld, G Byttebier, et al.
Plos One|July 28, 2010
Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSAMarjan W M Wassenberg, G Ardine de Wit, Ben A van Hout, et al.
European Journal of Epidemiology|February 5, 2004
Prevention comes of age?Luc G A Bonneux, Ben A van Hout, Johannes J M van Delden, et al.
Pageof 13

Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Prevention Science : the Official Journal of the Society for Prevention Research|March 4, 2011
Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behaviorMaartje A Raaijmakers, Jocelyne A Posthumus, Ben A van Hout, et al.
BMJ (Clinical Research Ed.)|July 26, 1997
Bone density and risk of hip fracture in men and women: cross sectional analysisC E De Laet, B A van Hout, H Burger, et al.
Pharmacoeconomics|September 19, 2002
Costs and effectiveness of using coumarins before, during and after coronary angioplastyJurrien M ten Berg, Johannas C Kelder, Thys H W Plokker, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2003
Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term useR M Klok, M J Postma, B A van Hout, et al.
Journal of Market Access & Health Policy|July 24, 2018
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UKEmilie Clay, Aurélien Jamotte, Peter Verhamme, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 18, 1998
[Economic evaluation of cardiology; background and application]B A van Hout, E S Goes, E W Grijseels, et al.
Clinical Therapeutics|May 17, 2003
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The NetherlandsBen A van Hout, Rogier M Klok, Jacobus R B J Brouwers, et al.
Anti-Cancer Drugs|May 18, 1999
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancerM G Groener, B M van Ineveld, G Byttebier, et al.
Plos One|July 28, 2010
Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSAMarjan W M Wassenberg, G Ardine de Wit, Ben A van Hout, et al.
European Journal of Epidemiology|February 5, 2004
Prevention comes of age?Luc G A Bonneux, Ben A van Hout, Johannes J M van Delden, et al.
Pageof 13